Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.
RA Hajjeh, L Privor-Dumm, K Edmond, R O'Loughlin, S Shetty, UK Griffiths, AP Bear, AL Cohen, A Chandran, A Schuchat, EK Mulholland, M Santosham
Vaccine | Published : 2010
The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.